

Lyra Therapeutics, Inc.
480 Arsenal Way
Watertown, MA 02472

May 18, 2022

Via EDGAR

Securities and Exchange Commission
Division of Corporation Finance
Office of Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Alan Campbell

Re: **Lyra Therapeutics, Inc.**
Registration Statement on Form S-3 Filed May 11, 2022
File No. 333-264864

To whom it may concern:

Pursuant to Rule 461(a) under the Securities Act of 1933, as amended, Lyra Therapeutics, Inc. (the "***Company***") hereby respectfully requests that the effective date of the Company's Registration Statement on Form S-3 (File No. 333-264864) be accelerated by the Securities and Exchange Commission to 4:00 p.m. Washington D.C. time on May 20, 2022 or as soon as practicable thereafter.

* * * *

The Company requests that we be notified of such effectiveness by a telephone call to Wesley C. Holmes of Latham & Watkins LLP at (617) 948-6027 and that such effectiveness also be confirmed in writing.

Very truly yours,

Lyra Therapeutics, Inc.

By: /s/ Jason Cavalier

Jason Cavalier
Chief Financial Officer

cc: Wesley C. Holmes, Latham & Watkins LLP